5 results
8-K
EX-99.2
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
2 Apr 24
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
7:32am
7.7/92.3 15.4/84.6 Race White %; (n) 92.6 (n=25) 92.0 (n=23) 92.3 (n=24) 92.3 (n=72) Black or African American %; (n) 3.7 (n=1) 8.0 (n=2) 7.7 (n=2) 6.4 … 25.0/75.0 21.6/78.4 Race White %; (n) 83.9 (n=26) 85.0 (n=17) 84.3 (n=43) Black or African American %; (n) 9.7 (n=3) 5.0 (n=1) 7.8 (n=4) Asian %; (n) 6.5
8-K
EX-99.2
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
4 Jan 24
Kiniksa Pharmaceuticals Provides Corporate Update
7:37am
%; (n) 92.6 (n=25) 92.0 (n=23) 92.3 (n=24) 92.3 (n=72) Black or African American %; (n) 3.7 (n=1) 8.0 (n=2) 7.7 (n=2) 6.4 (n=5) Asian %; (n) 3.7 (n=1
8-K
EX-99.2
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
22 Apr 20
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
8:07am
Race White (n) 65.2% (15) 80.8% (21) 73.5% (36) Black or African American (n) 21.7% (5) 11.5% (3) 16.3% (8) Asian (n) 8.7% (2) 0 4.1% (2) American
- Prev
- 1
- Next